AxoGen, Inc. (NASDAQ:AXGN) Shares Sold by EAM Investors LLC

EAM Investors LLC trimmed its position in AxoGen, Inc. (NASDAQ:AXGN - Free Report) by 47.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 36,547 shares of the medical equipment provider's stock after selling 33,529 shares during the quarter. EAM Investors LLC owned approximately 0.08% of AxoGen worth $602,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. State Street Corp lifted its holdings in AxoGen by 11.9% during the 3rd quarter. State Street Corp now owns 896,674 shares of the medical equipment provider's stock worth $12,571,000 after buying an additional 95,051 shares during the last quarter. Barclays PLC boosted its holdings in AxoGen by 119.3% in the third quarter. Barclays PLC now owns 72,036 shares of the medical equipment provider's stock valued at $1,010,000 after purchasing an additional 39,182 shares in the last quarter. Geode Capital Management LLC increased its stake in AxoGen by 3.2% in the third quarter. Geode Capital Management LLC now owns 1,010,508 shares of the medical equipment provider's stock valued at $14,170,000 after purchasing an additional 31,612 shares during the last quarter. Franklin Resources Inc. raised its holdings in AxoGen by 9.8% during the third quarter. Franklin Resources Inc. now owns 76,048 shares of the medical equipment provider's stock worth $1,084,000 after purchasing an additional 6,767 shares in the last quarter. Finally, Principal Financial Group Inc. purchased a new stake in shares of AxoGen during the 3rd quarter worth approximately $207,000. 80.29% of the stock is owned by hedge funds and other institutional investors.

AxoGen Stock Performance

AXGN stock traded down $0.39 during trading on Monday, hitting $15.18. The company had a trading volume of 278,023 shares, compared to its average volume of 426,462. AxoGen, Inc. has a 1-year low of $5.55 and a 1-year high of $21.00. The firm has a 50-day moving average price of $17.65 and a 200-day moving average price of $16.13. The company has a quick ratio of 2.47, a current ratio of 3.74 and a debt-to-equity ratio of 0.67. The firm has a market cap of $673.14 million, a PE ratio of -47.44 and a beta of 1.00.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Canaccord Genuity Group lifted their price target on shares of AxoGen from $22.00 to $26.00 and gave the stock a "buy" rating in a research note on Wednesday, February 26th. Cantor Fitzgerald reissued an "overweight" rating and issued a $24.00 target price on shares of AxoGen in a report on Wednesday, March 5th. Finally, Lake Street Capital began coverage on AxoGen in a research note on Monday, March 17th. They set a "buy" rating and a $30.00 price target on the stock. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $22.60.

Insider Activity

In related news, Director Amy Mcbride Wendell sold 5,000 shares of the firm's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $20.02, for a total value of $100,100.00. Following the completion of the sale, the director now owns 97,899 shares in the company, valued at $1,959,937.98. This trade represents a 4.86 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Erick Wayne Devinney sold 15,111 shares of the business's stock in a transaction that occurred on Wednesday, March 19th. The stock was sold at an average price of $17.50, for a total value of $264,442.50. Following the transaction, the insider now owns 217,762 shares in the company, valued at $3,810,835. The trade was a 6.49 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 7.00% of the company's stock.

AxoGen Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.